# Oral Ibrexafungerp (SCY-078) vs Standard-of-Care Following IV Echinocandin in the Treatment of Invasive Candidiasis

> **NCT02244606** · PHASE2 · COMPLETED · sponsor: **Scynexis, Inc.** · enrollment: 27 (actual)

## Conditions studied

- Mycoses
- Candidiasis, Invasive
- Candidemia

## Interventions

- **DRUG:** SCY-078
- **DRUG:** Fluconazole
- **DRUG:** Micafungin

## Key facts

- **NCT ID:** NCT02244606
- **Lead sponsor:** Scynexis, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-09
- **Primary completion:** 2016-06
- **Final completion:** 2016-08
- **Target enrollment:** 27 (ACTUAL)
- **Last updated:** 2024-06-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02244606

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02244606, "Oral Ibrexafungerp (SCY-078) vs Standard-of-Care Following IV Echinocandin in the Treatment of Invasive Candidiasis". Retrieved via AI Analytics 2026-06-07 from https://api.ai-analytics.org/clinical/NCT02244606. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*